Malladi et al., 2021 - Google Patents
Immunogenicity and protective efficacy of a highly thermotolerant, trimeric SARS-CoV-2 receptor binding domain derivativeMalladi et al., 2021
View PDF- Document ID
- 10952549692686357906
- Author
- Malladi S
- Patel U
- Rajmani R
- Singh R
- Pandey S
- Kumar S
- Khaleeq S
- van Vuren P
- Riddell S
- Goldie S
- Gayathri S
- Chakraborty D
- Kalita P
- Pramanick I
- Agarwal N
- Reddy P
- Girish N
- Upadhyaya A
- Khan M
- Kanjo K
- Bhat M
- Mani S
- Bhattacharyya S
- Siddiqui S
- Tyagi A
- Jha S
- Pandey R
- Tripathi S
- Dutta S
- McAuley A
- Singanallur N
- Vasan S
- Ringe R
- Varadarajan R
- Publication year
- Publication venue
- ACS Infectious Diseases
External Links
Snippet
The receptor binding domain (RBD) of SARS-CoV-2 is the primary target of neutralizing antibodies. We designed a trimeric, highly thermotolerant glycan engineered RBD by fusion to a heterologous, poorly immunogenic disulfide linked trimerization domain derived from …
- 108091005626 SARS-CoV-2 receptor-binding domain 0 title description 16
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Powell et al. | A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice | |
| Malladi et al. | Immunogenicity and protective efficacy of a highly thermotolerant, trimeric SARS-CoV-2 receptor binding domain derivative | |
| Swanson et al. | A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain | |
| Smith et al. | Immunogenicity of a DNA vaccine candidate for COVID-19 | |
| Saunders et al. | Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses | |
| Kang et al. | Rapid development of SARS-CoV-2 spike protein receptor-binding domain self-assembled nanoparticle vaccine candidates | |
| Watanabe et al. | Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine | |
| Watanabe et al. | Antibodies to a conserved influenza head interface epitope protect by an IgG subtype-dependent mechanism | |
| Berry et al. | Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology | |
| Morales-Núñez et al. | Overview of neutralizing antibodies and their potential in COVID-19 | |
| US20230285539A1 (en) | Vaccines against sars-cov-2 and other coronaviruses | |
| Hsieh et al. | Stabilized coronavirus spike stem elicits a broadly protective antibody | |
| Valdes-Balbin et al. | Molecular aspects concerning the use of the SARS-CoV-2 receptor binding domain as a target for preventive vaccines | |
| Sliepen et al. | Immunosilencing a highly immunogenic protein trimerization domain | |
| Corti et al. | Broadly neutralizing antiviral antibodies | |
| Xiong et al. | An mRNA-based broad-spectrum vaccine candidate confers cross-protection against heterosubtypic influenza A viruses | |
| Hauser et al. | Engineered receptor binding domain immunogens elicit pan-sarbecovirus neutralizing antibodies outside the receptor binding motif | |
| Musunuri et al. | Bringing immunofocusing into focus | |
| Isaacs et al. | Combinatorial FG immunogens as Nipah and respiratory syncytial virus vaccine candidates | |
| De Jong et al. | Development of broadly reactive influenza vaccines by targeting the conserved regions of the hemagglutinin stem and head domains | |
| Wen et al. | Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant | |
| Labriola et al. | Peptide–antibody fusions engineered by phage display exhibit an ultrapotent and broad neutralization of SARS-CoV-2 variants | |
| Braz Gomes et al. | Single-component multilayered self-assembling protein nanoparticles displaying extracellular domains of matrix protein 2 as a pan-influenza A vaccine | |
| Chao et al. | Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV | |
| Levi‐Schaffer et al. | Coronavirus disease 2019 and the revival of passive immunization: Antibody therapy for inhibiting severe acute respiratory syndrome coronavirus 2 and preventing host cell infection: IUPHAR review 31 |